Pre-Menstrual Syndrome Market
Pre-Menstrual Syndrome Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Pre-Menstrual Syndrome Market Size and Growth
The Pre-Menstrual Syndrome (PMS) market is experiencing significant growth due to increased awareness and diagnosis. The global PMS market size is projected to reach approximately $2 billion by 2028, driven by rising prevalence, innovation in treatments, and growing consumer awareness. Key trends include natural remedies and advancements in pharmaceutics.
Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Alva-Amco Pharmacal Cos., Inc.
◍ Bayer, Inc.
◍ Chattem, Inc. (Sanofi)
◍ DEKK-TEC, Inc.
◍ G. R. Lane Health Products Ltd
◍ McNeil Consumer Healthcare
◍ MetP Pharma AG
◍ Pherin Pharmaceuticals, Inc.
◍ Umecrine Mood AB
◍ Novartis AG
◍ GlaxoSmithKline Plc
The Pre-Menstrual Syndrome Market features key players like Bayer and GlaxoSmithKline, offering targeted treatments. Innovations from Alva-Amco and Pherin focus on symptom relief, while Umecrine enhances mood management. Collaborations and extensive distribution propel growth, with McNeil and Chattem contributing significantly to overall sales revenues, driving market expansion.
Market Segmentation
By Application
Hospitals
Clinic
Others
By Product
◍ Analgesics (Pain Killers)
◍ Oral Contraceptive Pills (OCPs) ◍ Gonadotropin-Releasing Hormone (GnRH) ◍ Antidepressants
Ovarian Suppressors
Diuretics
Benzodiazepines
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
